Yesterday, Samumed’s CEO Dr. Osman Kibar gave an interesting interview to Fierce Biotech (h/t reader “John Doe”). The most relevant part of this interview for us is:
“Its alopecia treatment is close behind, with approval anticipated in late 2021 or early 2022.”
Not a surprise as far as time frame goes, but Mr. Kibar seems confident that they will get approval. I am assuming he agreed with the above sentence in the interview or was quoted as such.
Not sure if other CEOs “anticipate” approval chances before Phase 3 trials are complete. I am hoping that Samumed has seen good results during the first year of ongoing Phase 3 trials in order to warrant this confidence.
The interview also has some interesting information about the scientific reasoning behind why Samumed’s products are safe despite targeting the critical Wnt pathway.
Rogaine (chemical name Minoxidil) is one of only two officially approved hair loss treatments in the US and EU. There are a number of mechanisms via how Minoxidil works to grow hair. Nowadays, most people use Rogaine 5% Minoxidil Foam rather than topical Minoxidil. Some people prefer to use high-strength Minoxidil.
The instructions on the packaging tell male users to apply Rogaine foam twice per day. However, many people choose to apply it just once per day instead.
There is some evidence that once a day use of Rogaine (Minoxidil 2% or 5%) is almost as effective as using it twice per day. The half-life of topical Rogaine is 22 hours.
Please closely read all the options in the below poll before voting. You can only vote once, and cannot edit your vote.
Poll: Rogaine Once or Twice per Day?
Due to the poll slowing down this site, I ended it early. Final results are shown below based on a total of 480 votes: